Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
Authors:
Top Cited Papers
Open Access
- 11 February 2026
- journal article
- equivalence trial
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 26 (6) , 614-626
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (2008501)
- National Health and Medical Research Council (1182950)
- National Health and Medical Research Council (1196068)
- National Health and Medical Research Council (1194702)
- Australian Centre of Research Excellence in Malaria Elimination (GNT2024622)
- Bill and Melinda Gates Foundation (INV-024389)
- Bill and Melinda Gates Foundation (INV-043618)
- Bill and Melinda Gates Foundation (2025377)
- Bill and Melinda Gates Foundation (GNT2018654)
- Bill and Melinda Gates Foundation (GNT2033264)
This publication has 28 references indexed in Scilit:
- 14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy studyThe Lancet Infectious Diseases, 2025
- Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trialThe Lancet, 2023
- Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysisThe Lancet Infectious Diseases, 2023
- Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning?The Lancet Infectious Diseases, 2023
- Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety studyThe Lancet Infectious Diseases, 2023
- Plasmodium vivax in the Era of the Shrinking P. falciparum MapTrends in Parasitology, 2020
- Resolving the cause of recurrent Plasmodium vivax malaria probabilisticallyNature Communications, 2019
- Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trialThe Lancet, 2019
- Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling studyThe Lancet, 2019
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976